Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer

Hajime Otsu, Eiji Oki, Ayae Ikawa-Yoshida, Hiroyuki Kawano, Koji Ando, Satoshi Ida, Yasue Kimura, Shinichi Aishima, Hiroshi Saeki, Masaru Morita, Shunji Kohnoe, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

Results from the Trastuzumab for Gastric Cancer (ToGA) trial highlighted the clinical significance of trastuzumab in the treatment of HER2 (Human Epidermal Growth Factor Receptor type 2)-positive gastric cancer. However, whether expression of HER2 is related to prognosis of gastric cancer is still controversial. A total of 360 consecutive patients with gastric cancer who underwent surgical resection in our Department from 1994 to 2007 were analyzed. We performed immunohistochemical analysis of HER2 expression. HER2 expression level was classified into four scores (0, 1+, 2+ and 3+). There were 37 (10%) patients with a score of 3+. A score of 3+ was defined as being HER2-positive. Recurrence-free survival was worse in HER2-positive cases (p=0.045). When the analysis was conducted with intestinal types of cancer, RFS was considerably worse in the HER2-positive group (p=0.011). HER2 expression may have potential as a prognostic factor for intestinal cancer types. Further research is warranted.

Original languageEnglish
Pages (from-to)2441-2446
Number of pages6
JournalAnticancer research
Volume35
Issue number4
Publication statusPublished - Apr 1 2015

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer'. Together they form a unique fingerprint.

Cite this